BACKGROUND: Current reference methods for evaluating gene amplification and expression of ERBB2 (also known as HER-2)-cell-based fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC)-are subjective and influenced by methods of tissue preparation and fixation. We developed and evaluated a novel, quantitative liquid-based FISH (L-FISH) assay that uses flow cytometry to detect ERBB2 gene amplification in breast cancer patients.
Human epidermal growth factor receptor 2 [(ERBB2, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian); also known as HER-2], an orphan receptor tyrosine kinase, is involved in the regulation of a wide spectrum of cell activities, including cell proliferation, differentiation, adhesion, and migration (1, 2 ) . ERBB2 overproduction occurs in 20%-30% of patients with invasive breast cancer (3 ) and is considered an adverse prognostic factor for clinical outcome (4, 5 ) . Amplification of the ERBB2 2 gene, located on chromosome 17q21, is the major underlying mechanism and accounts for approximately 97% of protein overproduction (6, 7 ) . Deregulated ERBB2 expression has also been shown to have potential prognostic implications in patients with ovarian, gastric, lung, colon, pancreatic, and prostate cancers (6, 8 -12 ) .
The approval of immunotherapy based on trastuzumab (Herceptin), a humanized anti-ERBB2 monoclonal antibody, has created an increasing clinical demand for a reliable laboratory assay to accurately measure ERBB2 status. An evaluation of ERBB2 status not only is relevant in monitoring trastuzumab therapy but also appears to be a predictive indicator of clinical responsiveness to a variety of treatment regimens. For example, ERBB2-overproducing breast cancers are often resistant to endocrine therapy (13, 14 ) ; ERBB2 amplification is correlated with resistance to radiation therapy (15 ) and may be associated with a clinical benefit from cyclophosphamide, methotrexate, and fluorouracil chemotherapy (16 ) ; and ERBB2 positivity may also be predictive of an enhanced response to doxorubicin and paclitaxel treatment modalities (17, 18 ) . Given the prognostic and therapeutic implications, ERBB2 testing is an indispensable prerequisite for good management of breast cancer patients.
ERBB2 expression and/or amplification can be detected by immunologic methods such as Western blotting, immunohistochemistry (IHC), 3 and ELISA, or by molecular approaches such as Southern blotting, fluorescence in situ hybridization (FISH), chromogenic or bright-field in situ hybridization, and real-time quantitative PCR (19, 20 ) . Most of these assays are cell based and require tissue-sample preparation, whereas ELISA and real-time quantitative PCR have the potential to be carried out on cell-free samples. IHC and FISH are the 2 most commonly used testing approaches in the clinical setting. FISH is more sensitive, specific, and accurate, but IHC is less labor-intensive, quicker, and more cost-effective and therefore has been adopted as the first-line method for routine and archival analysis of tissue samples (20 -22 ) . The prognostic evaluation of ERBB2 status with these tissue-based methods has been hampered by the limited availability of samples for testing. Once tumor tissues have been surgically removed, tissue-based methods are no longer applicable for detecting early recurrence, testing for metastasis, or monitoring therapeutic outcome. This fact narrows the ERBB2-testing window to the time of diagnosis. A test with the potential to accurately evaluate ERBB2 status from blood samples will remedy this situation.
We describe a novel molecular diagnostic assay, liquid-based FISH (L-FISH), that can be used to quantitatively measure ERBB2 amplification in both tissue and blood samples. This approach involves solution hybridization of sample DNA to labeled probes, DNA capture on streptavidin-coated microspheres, and fluorescence quantification via flow cytometry. In this study, we compared L-FISH results with those obtained with 2 US Food and Drug Administration (FDA)-approved methodsconventional FISH and IHC-for tissue sections and serum samples from breast cancer patients. Tissue-and serum-based L-FISH results showed high concordance with both conventional FISH and IHC results.
Materials and Methods

COLLECTION OF PATIENT SAMPLES
The study materials consisted of stored samples from 144 randomly selected patients with breast cancer: 22 stored serum samples and 122 formalin-fixed, paraffinembedded (FFPE) samples of primary tumor tissues. We cut 6 sections (4 -5 m) for IHC and FISH and sliced 3 additional 10-m sections from the same block to extract DNA for L-FISH. All tissue samples contained invasive carcinoma. There was no evidence of tumor cell dissemination into the blood for any of the blood samples used for L-FISH. Tissue samples were fixed in neutral buffered formalin for 6 -48 h; all testing was performed in a highthroughput testing laboratory.
DNA EXTRACTION AND NICK TRANSLATION
Genomic DNA samples from human breast cancer cell lines BT-474, SK-BR-3, and MCF-7 and from chronic myelogenous leukemia cell line K562 were purchased from the ATCC. To isolate breast tissue DNA, we used the QIAamp MinElute Virus Spin Kit (Qiagen) with some modifications. We deparaffinized FFPE tissue sections with xylene/ethanol, treated the sections with proteinase K, inactivated the proteinase by heating at 96°C for 10 min, and then purified the DNA by centrifugation through the kit's silica membrane-containing spin columns.
Cell-free circulating DNA from serum (200 L) was purified with the same Qiagen kit according to the manufacturer's protocol. All DNA samples were eluted in PCR-grade water (Ambion/Applied Biosystems). The quality and concentrations of all isolated DNA samples were estimated on a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies) from the ultraviolet absorbance spectra between 220 and 320 nm. Samples were analyzed further only when the DNA was of high purity (i.e., an A 260 /A 280 ratio Ͼ1.6).
We used Biotin-Nick Translation Mix (Roche Applied Science) to biotinylate purified DNA with biotin-16-dUTP. To obtain the highest sensitivity for detection, we adjusted the molar ratio of biotin-16-dUTP to dTTP in the mix to ensure that every 20th to 25th nucleotide in the newly synthesized DNA was labeled with biotin. The labeled fragments obtained in a typical nick-translation reaction showed a size distribution of 200 -500 bp.
L-FISH ASSAY
Fluorescein isothiocyanate (FITC)-labeled ERBB2 probes were generated with the Universal Linkage System (ULS™) (Kreatech Diagnostics). This ULS system allows efficient, nonenzymatic, and direct labeling of fluorochromes to the DNA molecule. For an internal reference, we had Sigma-Aldrich custom-synthesize a chromosome 17-specific single-copy oligonucleotide (17-SSC) end-labeled with Cy5 at the 5Ј end. The coordinates of this sequence are Chr17: 43964239 -43964288. We chose this sequence because of its singlecopy sequence composition, GC content (40%-55%), lack of potential secondary structure, and length (23 ) .
Labeled probes were hybridized to the appropriate amount of biotinylated DNA in the presence of Cot-1 and salmon sperm DNA (300 ng each) in Hybrisol VII hybridization solution (MP Biomedicals), denatured for 15 min at 87°C, and reannealed at 45°C for 2 h. To reduce nonspecific binding, we sequentially treated streptavidin-coated microspheres (Bangs Laboratories) with BlockAid (Invitrogen) and sheared salmon sperm DNA (100 g/mL) before conjugation. The annealed DNA mixture was then coupled to the streptavidin-coated microspheres in conjugation buffer (100 mmol/L Tris-HCl, pH 8.0, 1 g/L Tween 20, and 1 mol/L LiCl) for 1 h at room temperature. The coupled microspheres were washed once with 100 mL/L formamide/0.2ϫ standard saline citrate (0.03 mol/L NaCl and 0.003 mol/L sodium citrate) and twice with 0.2ϫ standard saline citrate. The amount of bead-bound DNA was estimated with the aid of SYBR Green (Invitrogen). We used the Alexa Fluor 488 Signal Amplification Kit (Invitrogen) to enhance FITC fluorescence. This kit uses 2 antibodies tagged with Alexa Fluor 488 -a rabbit anti-FITC antibody and a goat anti-rabbit IgG antibody. Microspheres were washed 3 times with 1ϫ PBS (2.7 mmol/L potassium chloride, 1.8 mmol/L potassium phosphate, 137 mmol/L sodium chloride, and 10.1 mmol/L sodium phosphate) containing 10 g/L BSA and analyzed on a FACSCanto flow cytometer (BD Biosciences). We measured the fluorescence emissions of FITC and allophycocyanin (which has the same spectrum as Cy5) and computed the mean fluorescence intensity of at least 5 000 events for each sample.
FISH ANALYSIS
For FISH analysis of ERBB2 amplification, we used the PathVysion HER-2 DNA Probe Kit (Vysis/Abbott Molecular) according to manufacturer's instructions. In brief, we prepared several paraffin sections (4 -5 m thick) from each breast tissue sample and subjected them to deparaffinization, rehydration, and protease digestion (37°C, 1-2 h) before we hybridized the sections overnight with fluorescently labeled probes for the ERBB2 gene and ␣-satellite DNA for chromosome 17 (CEP17). After appropriate posthybridization washing steps, we visualized dual-color fluorescence signals by fluorescence microscopy. We counted and scored the ERBB2 (orange) and CEP17 (green) signals in each of 30 nuclei. We interpreted samples with ERBB2/CEP17 signal ratios Ͼ2.2 as positive for amplification and signal ratios Ͻ1.8 as negative for amplification. Ratios between 1.8 and 2.2 were considered borderline results, and such samples were excluded from concordance studies. We also excluded cases with aneuploidy. Aneuploidy was defined as a mean chromosome 17 signal outside the range of 1.76 -2.25/cell.
IHC ASSAY
ERBB2 protein overexpression was measured with an FDA-approved HercepTest (Dako Corp.) and scored as recommended by experienced pathologists. Samples subjected to ERBB2 testing were fixed in 10% neutral buffered formalin for at least 6 h and not longer than 48 h. Careful attention was paid to the recommended exclusion criteria for performing and interpreting ERBB2 IHC assays (e.g., artifactual distortion of tissues, apoptotic or necrotic areas). IHC-stained slides were interpreted and scored on a scale of 0 to 3ϩ in accordance with the FDA-approved guidelines. IHC immunostaining of 3ϩ was considered to indicate ERBB2 overproduction, and 0/1ϩ immunostaining was considered negative for ERBB2 amplification. Samples with scores of 2ϩ were interpreted as inconclusive (equivocal) and were excluded from concordance studies.
IMPRECISION STUDY
We used 15 tissue and 15 serum control samples (5 samples each of low, medium, and high ERBB2 expression) to evaluate the imprecision of the L-FISH assay. We assessed intraassay (within-run) variation by analyzing 5 control samples on the same day and evaluated interassay (between-run) variation by measuring ERBB2/internal control ratios over a 5-day period. We then calculated within-and between-run CVs. CVs of Ͻ20% were considered to indicate acceptable performance for both within-run imprecision and betweenrun imprecision.
STATISTICAL ANALYSIS
Data were compared with the Fisher exact and nonparametric tests as appropriate. Tests included Spearman correlation, Wilcoxon matched pairs, KruskalWallis, and 2 tests. All tests were 2-tailed, and P values Ͻ0.05 were considered statistically significant. To assess the relationship between L-FISH ERBB2/17-SSC ratios and results for conventional FISH and IHC analyses, we also calculated 95% confidence intervals for the means in some studies. We used SigmaPlot (Systat Software) and Statistica (StatSoft) software for all statistical analyses.
Results
DETECTION OF ERBB2 AMPLIFICATION
To determine whether we could detect an ERBB2 signal by flow cytometry, we first tested DNA extracted from breast cancer cell lines BT-474 and MCF-7. ERBB2 signals were easily detected in BT-474 samples, as shown by the dramatic increase and upward shift of the FITC mean fluorescence intensity and the percent positivity of the microspheres (Fig. 1A) . The L-FISH assay showed a strong linear relationship between the FITC index and target DNA concentrations across 3 orders of magnitude (up to 100 ng DNA , Fig. 1B) ; the signal reached a plateau as the amount of input DNA increased above 100 ng (data not shown). With SYBR Green staining, we consistently estimated the maximum capacity of the microspheres at approximately 1 pg DNA/microsphere (data not shown). The curve of breast cancer cell line BT-474 also had a steeper slope than that of MCF-7, indicating a higher degree of ERBB2 gene amplification in BT-474, an observation in accord with previous reports (24, 25 ) .
To expand on our initial findings, we used L-FISH to quantify ERBB2 gene status in 3 well-established tumor cell lines with different ERBB2 copy numbers per nucleus: BT-474 (high amplification, approximately 50 -60 ERBB2 copies/nucleus), SK-BR-3 (moderate amplification, approximately 10 -20 ERBB2 copies/ nucleus), and MCF-7 (little or no amplification, approximately 2-3 ERBB2 copies/nucleus) (24, 25 ) . Leukemia line K562 (2 ERBB2 copies) was used as a control. The ERBB2/17-SSC ratios obtained corresponded with the ERBB2 copy number for each cell line and did not change appreciably with increased DNA concentration (Table 1) , providing proof-of-concept evidence that L-FISH could be a valid, sensitive assay for assessing ERBB2 status.
DETERMINATION OF CUTOFF VALUES FOR CLINICAL SAMPLES
To establish cutoff values for clinical samples, we used L-FISH to test 26 nonneoplastic FFPE tissues (11 breast, 5 lung, 5 lymph node, and 5 tonsil samples) and 52 nonneoplastic serum samples. The control groups were from individuals with nonneoplastic diseases, and their ages were similar to those of the patients with breast cancer. Tissue samples were carefully selected to exclude areas of necrosis or infection. The mean (SD) ERBB2/17-SSC ratios obtained with L-FISH were 1.38 (0.32) for nonneoplastic tissue samples and 1.35 (0.26) for serum samples from individuals without cancer. The optimal cutoff ratio for ERBB2 gene amplification was 2.13 for serum and 2.34 for tissue (3 SDs above the mean for nonneoplastic samples; Fig. 2) . Notably, ERBB2/17-SSC ratios derived from cell lines were much higher than those from FFPE tissues or sera, probably because of the poorer quality and lower quantity of tumor DNA available from clinical samples, particularly when tumors are small and contaminated with nonneoplastic or apoptotic/necrotic elements (26 ) .
ANALYTICAL ASSESSMENT OF IMPRECISION
The imprecision results obtained for the ERBB2 L-FISH assay with 3 levels of controls (low, medium, and high) from tissue and serum samples are presented in Table 2 . The interassay and intraassay reproducibilities were very high for all 30 data points (CVs of Ͻ20%, Table 2 ). Interassay CVs for tissue samples were 3.7%-13%, and serum samples exhibited higher interassay CVs (12%-19%). Intraassay CVs were relatively low for both sample types (2.8%-6.3%). We also used L-FISH to test sera from 22 unselected breast cancer patients for ERBB2 gene amplification and compared the results with those obtained with conventional FISH and IHC (IHC 3ϩ samples reflexed to FISH) done on FFPE tissues from the same patients. Serum L-FISH results exhibited 91% concordance with tissuebased IHC/FISH results (Table 3 , bottom). L-FISH showed ERBB2 gene amplification in 3 cases, 2 of which were considered positive by IHC and conventional FISH. Only one of the 19 cases considered negative by L-FISH was scored positive by IHC and conventional FISH.
We drew ROC curves to further confirm the concordance between L-FISH and conventional FISH or IHC results (Fig. 3) . Again, L-FISH detection of ERBB2 amplification displayed substantially correlation with FISH or IHC results.
DISTRIBUTION OF L-FISH ERBB2 RATIOS ACCORDING TO AMPLIFICATION STATUS AS ASSESSED BY IHC AND CONVENTIONAL FISH
We 
Discussion
We have described a novel approach that can evaluate ERBB2 amplification in both cell-free and tissue/cell extracts. This approach uses probes in a fashion similar to that of conventional FISH, but hybridization occurs in solution (liquid format) rather than on a slide (solid support). Multiple methods are currently used for determining ERBB2-amplification status. Tissue-based testing, including conventional FISH and IHC, has the advantage of assessing ERBB2 amplification in intact cells; however, these methods can be subjective, laborious, and time-consuming if large numbers of clinical samples are to be tested. Neither method is applicable to cell-free samples. L-FISH, on the other hand, has the advantages of automation and a high-throughput capacity and allows levels of ERBB2 gene amplification to be measured in either tissue or cell-free samples. The sensitivity and accuracy of L-FISH could be further enhanced by macro-or microdissection of tumor tissues to eliminate dilution of the apparent ERBB2 copy number by nontumor cells in the samples.
We first evaluated the L-FISH assay by assessing 4 cell lines: BT-474, SK-BR-3, MCF-7, and K562. The ERBB2/17-SSC ratios obtained for all 4 cell lines were consistent with the ERBB2 gene dosages reported for other methods (24, 25 ) and had a broader dynamic range, indicating that L-FISH has the potential to distinguish between low and nonpathologic ERBB2 copy numbers. These results demonstrate the degree of correctness that can be achieved with this assay. Interestingly, the optimal cutoff ratios for L-FISH with FFPE and serum samples were 2.34 and 2.13, respectively, similar to the arbitrary cutoff value of 2.2 for conventional FISH.
Although conventional FISH is generally considered the comparison method for detecting ERBB2 gene amplification, our L-FISH assay could provide an attractive alternative to FISH, especially in laboratories that are familiar with flow cytometry. In our study, we first compared L-FISH with conventional FISH and IHC methods with a retrospective series of FFPE breast cancer samples. L-FISH showed good concordance with both conventional FISH and IHC methods (84.4% and 78.8%, respectively). Our data are consistent with the majority of correlation results reported for several validated ERBB2 assays of FFPE tissues. For example, the FISH and IHC methods have a reported concordance of 85%-95% (27, 28 ) , chromogenic in situ hybridization has shown a 83-100% association with FISH (29, 30 ) , and quantitative PCR and FISH/IHC methods exhibit a concordance of 79%-100% (31) (32) (33) . A recent large study designed to address the reproducibility of FISH and IHC also revealed a certain degree of discordance between central and local laboratories, with concordance rates of 77.5% for IHC to IHC, 92% for FISH to FISH, and 79% for FISH to IHC (34 ) . The discrepancies between L-FISH and FISH/IHC results (false-negative cases) could mainly be ascribed to the dilution of cells carrying amplified genes by nontumor cells (35, 36 ) . Thus, use of a laser-assisted microdissection step should enhance the reliability of L-FISH detection of ERBB2 gene amplification. Several FFPE cases classified as positive by L-FISH but negative by FISH/IHC could have resulted from difficulties in detecting and counting the signals on histologic sections because of the effects of the fixative, tissue permeability of antibody or probe, and antigen-or DNA-accessibility problems (21, 22, 27 ) . The isolation of sample DNA in L-FISH should allow a more accurate and robust signal readout than a fluorescent or chromogenic signal on histologic slides in FISH/IHC, where overlapping cell layers and tissue debris are often prevalent. The application of a dual-color L-FISH technique, with both a probe for the ERBB2 gene and a probe for a single-copy sequence on chromosome 17, has the advantage of providing an accurate estimate of gene amplification. Nevertheless, a second reference sequence could be added to our assay to address aneuploidy (37 ) and to make L-FISH analysis more consistent with the conventional FISH methodology.
Accumulating evidence has demonstrated the presence of substantially higher amounts of free circulating DNA in the plasma or serum of cancer patients than in healthy individuals (38, 39 ) . A noninvasive assay for tumor-related genetic aberrations that uses serum/plasma DNA is thus desirable for assessing prognosis and therapy stratification. Our investigation of the use of L-FISH with a single-copy reference gene has demonstrated that the ERBB2/17-SSC ratio in serum is a valuable indicator of ERBB2 gene amplification and that serum L-FISH assay results are strongly concordant with tissue IHC/FISH data (91%).
In summary, the L-FISH assay is fast, objective, cost-effective, and easily automated; it therefore can offer a high degree of standardization and reproducibility. Furthermore, it is easily applicable to clinical samples from breast cancer patients and produces results that have good concordance with IHC results for corresponding histologic sections or with data obtained by conventional FISH. This noninvasive assay can be used when primary tumor samples are unavailable and eliminates the need for biopsy. L-FISH could also be an attractive alternative method for determining ERBB2 status when tissue results are discordant; however, flow cytometry instrumentation and expertise must be available to perform this type of testing. In addition, morphologic evaluation of the FISH findings is not possible when L-FISH is used. Although there is a need to prospectively collect clinical data from a large set of patients (especially those with equivocal results for IHC and conventional FISH) to provide clinical verification of the accuracy of L-FISH, our results are promising and warrant pursuing such study.
